The rationale for the use of RRA is to decrease the risk of clinical tumor recurrence and to improve the sensitivity and specificity of follow-up testing via periodic serum thyroglobulin (Tg) measurement and radioiodine scanning.10–13 Verburg et al14 showed that successful RRAs could reduce the recurrence rates and improve survival rates, and that no survival difference after complete RRA was observed between initially low-risk and high-risk patients. Here, TG is linked to neoplasm.